Monte Rosa says Novartis starts Phase 2 trial of MRT-6160 in Sjögren's disease, triggers USD 50 million milestone
GLUE•Novartis starts Phase 2 trial of MRT-6160 in Sjögren's disease
- Novartis initiated a Phase 2 study of VAV1-directed molecular glue degrader MRT-6160 (DDY391) in Sjögren’s disease.
- Monte Rosa will receive a USD 50 million milestone tied to the study’s first patient visit.
- No new trial results were presented; the study will assess whether MRT-6160 can improve disease outcomes while remaining safe and tolerable.
- The trial is designed to support Phase 3 dose selection, reinforcing the program’s progression under the Novartis license.
Related News
Quantum Cyber buys Lambda Hyperplane AI cluster with eight Nvidia A100 GPUs
NVDA•
METALS-Copper jumps to hits record high on weak supply outside US
XLB•
